Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 1,847 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: pembrolizumab Clear all
Recruiting Phase 2 Interventional

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

NCT04253964
View directory record Official record
Conditions
Nonsmall Cell Lung Cancer, Performance Status
Interventions
Pembrolizumab, Atezolizumab, Cemiplimab-Rwlc, Carboplatin, Paclitaxel, Nab paclitaxel, Pemetrexed, Cisplatin, Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13), QLQ-C30 Global Health/Quality of Life Questionnaire, COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes, PROMIS and FACT-G Questionnaires, Sleep Disorder Assessments (ISI, Berlin Sleep Questionnaire)
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 5:10 AM EDT
Active, not recruiting Phase 2 Interventional

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

NCT03485209
View directory record Official record
Conditions
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
Interventions
tisotumab vedotin, pembrolizumab, carboplatin, cisplatin
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
124
States / cities
Encinitas, California • La Jolla, California • Sacramento, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 30, 2026, 5:10 AM EDT
Not listed Early Phase 1 Interventional

Pembrolizumab Plus Y90 Radioembolization in HCC Subjects

NCT03099564
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Pembrolizumab, Y90 radioembolization
Drug · Device
Lead sponsor
Ashwin Somasundaram
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
3
States / cities
Indianapolis, Indiana • Chapel Hill, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 30, 2026, 5:10 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy

NCT04454528
View directory record Official record
Conditions
Breast Cancer
Interventions
Hypofractionated radiotherapy, Pembrolizumab infusion, Blood and tissue sampling
Radiation · Drug · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 30, 2026, 5:10 AM EDT
Recruiting Phase 1Phase 2 Interventional

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

NCT05501665
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage III Lung Cancer
Interventions
Biospecimen Collection, Carboplatin, Computed Tomography, Fludeoxyglucose F-18, Nab-paclitaxel, Pembrolizumab, Pemetrexed, Positron Emission Tomography, Radiation Therapy, [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan, Ipilimumab, Nivolumab, Cemiplimab, Atezolizumab
Procedure · Drug · Other + 2 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 30, 2026, 5:10 AM EDT
Recruiting Phase 1Phase 2 Interventional

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

NCT06780111
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Pembrolizumab, I-DXd, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU), Oxaliplatin, Sacituzumab tirumotecan, Rescue Medication
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 30, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

NCT04013672
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
Pembrolizumab, SurVaxM, Sargramostim, Montanide ISA 51
Drug
Lead sponsor
David Peereboom
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 30, 2026, 5:10 AM EDT
Not listed Phase 2 Interventional

Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.

NCT04116775
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Metastatic
Interventions
Fecal microbiota transplant, Pembrolizumab, Enzalutamide
Biological · Drug
Lead sponsor
Julie Graff, MD
Federal
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 30, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma

NCT02644967
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
IMO-2125, Ipilimumab
Drug
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
10
States / cities
Tucson, Arizona • Tampa, Florida • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 30, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer

NCT02865811
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Pembrolizumab, Pegylated Liposomal Doxorubicin (PLD)
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Boston, Massachusetts • Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 30, 2026, 5:10 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

NCT04768881
View directory record Official record
Conditions
Locally Advanced Unresectable or Metastatic Melanoma
Interventions
Selinexor, Pembrolizumab
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
13
States / cities
Los Angeles, California • Pasadena, California • Plantation, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 30, 2026, 5:10 AM EDT
Terminated Phase 2 Interventional Results available

Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers

NCT04171219
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions
Pembrolizumab, Talabostat Mesylate
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 30, 2026, 5:10 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

NCT03137771
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
3-Dimensional Conformal Radiation Therapy (3D-CRT), Docetaxel, Gemcitabine, Intensity-Modulated Radiation Therapy (IMRT), Pemetrexed Disodium, Stereotactic Body Radiation Therapy (SBRT), Erlotinib Hydrochloride, Pembrolizumab
Radiation · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
296
States / cities
Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 228 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 30, 2026, 5:10 AM EDT
Recruiting Phase 1 Interventional

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

NCT04389632
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms
Interventions
sigvotatug vedotin, pembrolizumab, cisplatin, carboplatin
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
106
States / cities
Anchorage, Alaska • Fayetteville, Arkansas • Rogers, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 30, 2026, 5:10 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

NCT07811193
View directory record Official record
Conditions
Colorectal Adenocarcinoma
Interventions
VVD-133214, Pembrolizumab
Drug
Lead sponsor
Vividion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Tucson, Arizona • Ann Arbor, Michigan • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 30, 2026, 5:10 AM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer

NCT03425006
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Itacitinib, Pembrolizumab
Drug · Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 30, 2026, 5:10 AM EDT
Recruiting Phase 1 Interventional

Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers

NCT04295863
View directory record Official record
Conditions
Metastatic Cancer
Interventions
Nivolumab Standard, Pembrolizumab Standard, Nivolumab Extended, Pembrolizumab Extended
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 30, 2026, 5:10 AM EDT
Recruiting Phase 1 Interventional

Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma

NCT06514898
View directory record Official record
Conditions
Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma
Interventions
TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Td vaccine, autologous HSCs, Pembrolizumab
Biological · Drug
Lead sponsor
University of Florida
Other
Eligibility
4 Years to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 30, 2026, 5:10 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

NCT04380636
View directory record Official record
Conditions
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
Pembrolizumab, Olaparib, Placebo for olaparib, Etoposide, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed, Thoracic Radiotherapy, Durvalumab
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
33
States / cities
Mobile, Alabama • Jonesboro, Arkansas • Fullerton, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 30, 2026, 5:10 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)

NCT04009681
View directory record Official record
Conditions
Metastasis
Interventions
THOR-707, Checkpoint inhibitor, anti-EGFR antibody
Drug
Lead sponsor
Synthorx, Inc, a Sanofi company
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Scottsdale, Arizona • Denver, Colorado • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 30, 2026, 5:10 AM EDT
Terminated Phase 2 Interventional Results available

Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer

NCT04936230
View directory record Official record
Conditions
Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Pembrolizumab, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy
Procedure · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
83
States / cities
Littleton, Colorado • Bloomington, Illinois • Canton, Illinois + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 30, 2026, 5:10 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

NCT03506360
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma
Interventions
Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 30, 2026, 5:10 AM EDT
Terminated Phase 2 Interventional Results available

Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

NCT06046482
View directory record Official record
Conditions
Head Neck, Squamous Cell Carcinoma of Head and Neck
Interventions
Pembrolizumab, Magrolimab, cetuximab, Docetaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 30, 2026, 5:10 AM EDT
Not yet recruiting Phase 3 Interventional

Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer

NCT07867002
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Metastatic Endometrial Cancer, Endometrial Cancer, Recurrent Endometrial Cancer
Interventions
anti-PD1 agent therapy - 1 year, anti-PD1 agent therapy - 2 years
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
6
States / cities
Cary, North Carolina • Chapel Hill, North Carolina • Garner, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 30, 2026, 5:10 AM EDT